Nicholas J Skertich1, Justin Gerard1, Jennifer Poirier1, Martin Hertl2, Sam G Pappas1, Erik Schadde2, Xavier M Keutgen3. 1. Department of Surgery, Division of Surgical Oncology, Rush University Medical Center, 1750 W. Harrison Street, Jelke Building Suite 785, Chicago, IL, 60612, USA. 2. Department of Surgery, Division of Transplant Surgery, Rush University Medical Center, Chicago, IL, USA. 3. Department of Surgery, Division of General Surgery and Surgical Oncology, Endocrine Research Program, The University of Chicago Medicine and Biological Sciences Division, 5841 S. Maryland Ave, Chicago, IL, 60637, USA. xkeutgen@surgery.bsd.uchicago.edu.
Abstract
BACKGROUND: Venous thromboembolism (VTE) occurs at high incidence in abdominal cancer surgery; therefore, a 4-week postoperative VTE prophylaxis is advocated. However, most patients with neuroendocrine tumors (NETs) have more favorable prognoses. This study aimed to determine the incidence of VTE in patients with abdominal NETs, compare these rates to other abdominal malignancies, and identify VTE risk factors. METHODS: The ACS-NSQIP database was queried to identify patients with abdominal NETs and other abdominal malignancies who underwent surgery from 2008 to 2015. A 30-day postoperative VTE incidence for each group was compared. Univariable and multivariable analyses were used to identify VTE risk factors. RESULTS: Of the 7226 operations for patients with benign (2154) and malignant (5072) abdominal NETs, 144 patients experienced a VTE without significant differences between groups. Subgroup analysis revealed a spectrum of VTE rates. Compared to VTE rates of other abdominal malignancies, patients with benign (1.1% vs. 2.4%, p < 0.001) or malignant (1.7% vs. 2.4%, p < 0.001) non-pancreatic abdominal NETs had significantly lower rates, malignant pancreatic NETs (PNETs) (3.4% vs. 2.4%, p = 0.03) had significantly higher rates, and benign PNETs (3.2% vs. 2.4%, p = 0.21) had comparable rates. Multivariable analysis identified pre-operative albumin (p < 0.001), bleeding disorders (p < 0.001), operative time (p < 0.001), and having a PNET (p = 0.04) as risk factors for VTE in abdominal NET patients. CONCLUSION: Routine extended VTE prophylaxis after surgery may be necessary in PNETs, but probably unnecessary in other abdominal NETs. However, clinicians should use risk factors identified in this study when considering to forego extended VTE prophylaxis in NET patients.
BACKGROUND:Venous thromboembolism (VTE) occurs at high incidence in abdominal cancer surgery; therefore, a 4-week postoperative VTE prophylaxis is advocated. However, most patients with neuroendocrine tumors (NETs) have more favorable prognoses. This study aimed to determine the incidence of VTE in patients with abdominal NETs, compare these rates to other abdominal malignancies, and identify VTE risk factors. METHODS: The ACS-NSQIP database was queried to identify patients with abdominal NETs and other abdominal malignancies who underwent surgery from 2008 to 2015. A 30-day postoperative VTE incidence for each group was compared. Univariable and multivariable analyses were used to identify VTE risk factors. RESULTS: Of the 7226 operations for patients with benign (2154) and malignant (5072) abdominal NETs, 144 patients experienced a VTE without significant differences between groups. Subgroup analysis revealed a spectrum of VTE rates. Compared to VTE rates of other abdominal malignancies, patients with benign (1.1% vs. 2.4%, p < 0.001) or malignant (1.7% vs. 2.4%, p < 0.001) non-pancreatic abdominal NETs had significantly lower rates, malignant pancreatic NETs (PNETs) (3.4% vs. 2.4%, p = 0.03) had significantly higher rates, and benign PNETs (3.2% vs. 2.4%, p = 0.21) had comparable rates. Multivariable analysis identified pre-operative albumin (p < 0.001), bleeding disorders (p < 0.001), operative time (p < 0.001), and having a PNET (p = 0.04) as risk factors for VTE in abdominal NET patients. CONCLUSION: Routine extended VTE prophylaxis after surgery may be necessary in PNETs, but probably unnecessary in other abdominal NETs. However, clinicians should use risk factors identified in this study when considering to forego extended VTE prophylaxis in NET patients.
Authors: David Bergqvist; Giancarlo Agnelli; Alexander T Cohen; Amiram Eldor; Paul E Nilsson; Anne Le Moigne-Amrani; Flavia Dietrich-Neto Journal: N Engl J Med Date: 2002-03-28 Impact factor: 91.245
Authors: M S Rasmussen; L N Jorgensen; P Wille-Jørgensen; J D Nielsen; A Horn; A C Mohn; L Sømod; B Olsen Journal: J Thromb Haemost Date: 2006-08-01 Impact factor: 5.824
Authors: Vinita Bahl; Hsou Mei Hu; Peter K Henke; Thomas W Wakefield; Darrell A Campbell; Joseph A Caprini Journal: Ann Surg Date: 2010-02 Impact factor: 12.969
Authors: James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans Journal: J Clin Oncol Date: 2008-06-20 Impact factor: 44.544
Authors: William H Geerts; Graham F Pineo; John A Heit; David Bergqvist; Michael R Lassen; Clifford W Colwell; Joel G Ray Journal: Chest Date: 2004-09 Impact factor: 9.410
Authors: Gary H Lyman; Alok A Khorana; Anna Falanga; Daniel Clarke-Pearson; Christopher Flowers; Mohammad Jahanzeb; Ajay Kakkar; Nicole M Kuderer; Mark N Levine; Howard Liebman; David Mendelson; Gary Raskob; Mark R Somerfield; Paul Thodiyil; David Trent; Charles W Francis Journal: J Clin Oncol Date: 2007-10-29 Impact factor: 44.544
Authors: Karl Y Bilimoria; David J Bentrem; Jeffrey D Wayne; Clifford Y Ko; Charles L Bennett; Mark S Talamonti Journal: Ann Surg Date: 2009-01 Impact factor: 12.969
Authors: Selwyn O Rogers; Ravi K Kilaru; Patrick Hosokawa; William G Henderson; Michael J Zinner; Shukri F Khuri Journal: J Am Coll Surg Date: 2007-06 Impact factor: 6.113
Authors: Maya E Lee; Yashira M Ortega-Sustache; Sunita K Agarwal; Aisha Tepede; James Welch; Adel Mandl; Rashika Bansal; Amit Tirosh; Paolo Piaggi; Craig Cochran; William F Simonds; Lee S Weinstein; Jenny E Blau Journal: J Clin Endocrinol Metab Date: 2021-01-23 Impact factor: 5.958